Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability

ATG-022 and CLINCH Study Overview ATG-022 and CLINCH Study Overview Key Results Presented Conclusions and Outlook Forward-looking statementsPlease refer:https://www.antengene.com/newsinfo/442 For more information, please contact: Investor Contacts:Donald LungE-mail:donald.lung@antengene.com   BD Contacts:Ariel GuoE-mail:ariel.guo@antengene.com   Logo -https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg View original content:...

ATG-022 and CLINCH Study Overview

Key Results Presented

Conclusions and Outlook

Forward-looking statements
Please refer: https://www.antengene.com/newsinfo/442

For more information, please contact:

Investor Contacts:
Donald Lung
E-mail: donald.lung@antengene.com 

BD Contacts:
Ariel Guo
E-mail: ariel.guo@antengene.com 

Logo - https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/antengene-presents-latest-atg-022-clinical-data-at-esmo-2025-demonstrating-efficacy-across-all-cldn18-2-expression-levels-and-exceptional-tolerability-302588831.html